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Abstract
Background: Severe dysphagia may occur in the immune mediated necrotizing myopathies (IMNM). Neck swelling
and severe dysphagia as the initial symptoms upon presentation has not been previously described.
Case presentation: A 55-year-old male with a 4 week history of neck swelling, fatigue, dysphagia, myalgias, night
sweats, and cough was admitted for an elevated CK. He underwent extensive infectious and inflammatory
evaluation including neck imaging and muscle biopsy.
Neck CT and MRI showed inflammation throughout his strap muscles, retropharyngeal soft tissues and deltoids.
Infectious work up was negative. Deltoid muscle biopsy demonstrated evidence of IMNM. Lab tests revealed
anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies confirming the diagnosis of HMGCR
IMNM.
Conclusions: HMGCR IMNM is a rare and incompletely understood disease process. Awareness of HMGCR IMNM
could potentially lead to earlier diagnosis, treatment and improved clinical outcomes as disease progression can be
rapid and severe.
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Background
The idiopathic inflammatory myopathies consist of rare
autoimmune disorders that affect muscle as well as lung,
skin, joints and other organ systems. They are character-
ized by marked symmetrical proximal muscle weakness.
There is frequent CK elevation and electromyogram
demonstrates a myopathy. While they often share
clinical features, they can also have unique muscle
biopsy findings. More recently it has been shown that
approximately 60 % of patients with autoimmune myop-
athy have a myositis-specific autoantibody, each of which
is associated with a distinct clinical phenotype. Thus future
classification of these myopathies will include antibody
patterns [1].
Immune mediated necrotizing myopathy (IMNM) has
been recognized as a specific autoimmune myopathy
that accounts for 19 % of all inflammatory myopathies
[2]. In contrast to the idiopathic inflammatory myop-
athies which are characterized histopathologically by an
inflammatory exudate, IMNM muscle biopsies show
prominent fiber necrosis with minimal or no inflamma-
tion. Much attention has recently focused on IMNM
associated with autoantibodies that recognize 3-hydroxy-
3-methylglutaryl-coenzyme A reductase (HMGCR), the
pharmacological target of statins [3]. HMGCR IMNM
presents with symmetric proximal arm and leg weak-
ness, myalgias, dysphagia and arthralgias [4]. While
dysphagia occurs in about 20–35 % of patients [3, 5],
prominent head and neck symptoms as the presenting
complaint have not been described.
HMGCR IMNM has an aggressive and debilitating
clinical course characterized by significant muscle ne-
crosis. It is highly associated with current statin use,
prior statin exposure and also can be idiopathic in a
small number of cases but differs from statin induced
myopathy [6–8]. Statin induced myopathy, is commonly
* Correspondence: Ngox0073@umn.edu
1Division of Rheumatology, University of Minnesota Medical School, MMC
108 Mayo, 8108A, 420 Delaware St SE, Minneapolis, MN 55455, USA
Full list of author information is available at the end of the article
© 2016 Ngo et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ngo et al. BMC Ear, Nose and Throat Disorders  (2016) 16:7 
DOI 10.1186/s12901-016-0027-3
characterized by myalgias with statin use that stop with
discontinuation of the offending agent, and is a separate
non-autoimmune entity [9]. On the other hand, HMGCR
IMNM is an autoimmune disease that requires specific
therapy and possibly long-term immunosuppression.
HMGCR IMNM is associated with dysphagia in up to
35 % of patients, symmetric proximal muscle weakness in
95 %, distal muscle weakness in 41 %, and dyspnea in
37 %. CKs over 6000 and significant necrosis on muscle
biopsy are commonly seen [6–8].
In 2011, a novel antibody to HMGCR was discovered
in 6 % of a cohort of autoimmune inflammatory myositis
patients (n = 750) at Johns Hopkins University School of
Medicine [10]. Two-thirds of the patients had prior
statin exposure. All patients with anti-HMGCR antibody
IMNM demonstrated prominent necrosis with varying
levels of inflammation on pathology. Statin-naïve pa-
tients were younger but the two subgroups were indis-
tinguishable on pathology. Subsequent research supports
the theory that this process is both due to genetic and
environmental factors. Patients with HLA class II allele
DRB1*11:01 have been shown to have an increased risk
of developing HMGCR IMNM [11]. One possible model
has been proposed by Mammen et al. HMGCR is an
enzyme target of statins and has been shown to be
upregulated in skeletal muscle cells that are exposed to
statins in vivo [12]. Increased expression of the HMGCR
triggers an immune response with formation of HMGCR
antibodies and resultant skeletal muscle destruction and
regeneration. In addition, regenerating muscle cells have
also been demonstrated to increase expression of HMGCR
[10] thereby potentiating the process over an extended
period of time even after statin exposure is removed.
Treatment of anti-HMGCR IMNM requires several
agents. Prednisone monotherapy is inadequate in up to
90 % of patients and most patients required 2 or more
immunosuppressives [3]. Relapse rate is approximately
50–55 % in patients that taper off therapy [3, 6]. IVIG
within the first three months of presentation has poten-
tially promising outcomes with patients achieving signifi-
cant improvement at 6 months [3, 13].
Case presentation
A 55 year old African American male was admitted to
the hospital with a 4 week history of difficulty swallow-
ing, hoarseness, fatigue, neck swelling, night sweats and
a 20 lb weight loss. He had no muscle weakness. He had
type II diabetes mellitus and hyperlipidemia. His medica-
tions included atorvastain 40 mg daily which he was
taking for 2 years. There was no history of rhabdomyoly-
sis, or autoimmune disease.
On exam, he was afebrile with normal oxygen satur-
ation on room air. His voice was notably hoarse and he
had difficulty clearing his secretions. His neck was
swollen symmetrically, non-tender, and without lymph-
adenopathy. Cardiovascular, pulmonary and gastrointestinal
examination was unremarkable. Strength was 5/5 through-
out, and he was able to stand and walk independently.
There were no vasculitic skin lesions.
Basic hematological and chemistry studies were obtained
and were within normal limits. His creatine kinase (CK)
was 45,233 U/L (normal <120 U/L), AST was 835 U/L
(normal <66 U/L), ALT was 277 U/L (normal <69 U/L)
and aldolase was 83 U/L (normal <8.1 U/L). Basic
autoimmune studies including anti-dsDNA, anti-Smith,
anti-La, anti-Scl-70, anti-centromere, anti-cardiolipin, and
anti-neutrophil cytoplasmic (ANCA) antibodies were all
negative. Anti-Ro antibodies were positive. In addition,
complement levels and immunoglobulin levels were
normal. Infectious disease evaluations for all viral, fun-
gal and bacterial etiologies were negative. Additional
pertinent laboratory findings are displayed in Table 1.
Video swallow study revealed significant oropharyngeal
dysphagia.
Neck CT and MRI were suggestive of presumed infec-
tious retropharyngeal exudate and phlegmon extending
from the skull base to the upper thoracic region. There
was diffuse inflammation of neck strap muscles (Fig. 1
panel a). Otolaryngology and infectious diseases were
both consulted to assess for retropharyngeal abscess in
the setting of severe dysphagia and neck soft tissue
swelling. Broad spectrum antibiotics were started, how-
ever, the patient’s clinical status worsened. On the fifth
day of admission, the patient developed weakness of the
shoulders and an MRI of the shoulders revealed marked
Table 1 Pertinent lab values across management course
Day # of Management 1 5 8 20 48
Creatine Kinase (CK) (0–170 U/L) 28205 31986 45223 11246 2682
Anti-HMGCR Antibody (<20 U) - >200 - - 104
Creatinine (0.66–1.25 mg/dL) 1.285 0.82 0.81 0.93 0.56
Erythrocyte Sedimentation
Rate (ESR) (0–15 mm/h)
>68 49 - - -
C-Reactive Protein (CRP)
(0.0–0.9 mg/dL)
7.4 3.8 3.3 - -
Hemoglobin (13.5–17.5 g/dL) 14.6 - - 14 11.0
Platelets (150–450 k/uL) 419 - - 216 296
White Blood Count (4.0–11.0 k/uL) 9.1 - - 32.4 10.4
Aspartate transaminase (AST)
(0–66 U/L)
786 847 - 441 278
Alanine transaminase (ALT)
(0–69 U/L)
268 304 - 336 374
Alkaline Phosphatase (38–126 U/L) 77 47 - 28 59
Bilirubin, Direct (0.0–.3 mg/dL) 0 0 - 0 0
Bilirubin, Total (0.2–1.3 mg/dL) 1.2 0.9 - 1.1 0.3
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swelling, edema and inflammation of the deltoids and
neck muscles. A muscle biopsy was performed of the left
deltoid muscle and pathology revealed an inflammatory
myopathy notable for myriad necrotic fibers, sometimes
involving entire fascicles, many replaced by macrophages.
An inflammatory exudate was present in perivascular
regions in perimysium especially where the necrotic fibers
were present. Myositis specific antibodies including Jo-1,
Mi-2, PL-7, PL-12, SRP, EJ and OJ were negative. Subse-
quently, anti-HMGCR antibody testing was extremely
positive at >200 U (normal <20 U).
He rapidly developed respiratory weakness with nega-
tive inspiratory force and vital capacity of -55 cm H2O
(expected >80 cm H20) and 3.72 L (expected >3.8 L)
respectively. This was followed by rapid and severe
weakness of proximal upper and lower extremity mus-
cles with inability to abduct his arms and stand up from
seated position without assistance. He required a feeding
tube for nutrition.
Treatment was initiated with IV methylprednisolone
500 mg daily for 3 days, which was followed by 5 days of
plasmapheresis, followed by intravenous immunoglobu-
lin (IVIG) therapy with 1 g/kg daily for 2 days.
Follow-up CT scan of the neck after treatment re-
vealed significant improvement in inflammation of strap
muscles and retropharyngeal swelling (Fig. 1 panel b).
The patient improved and was discharged home on only
prednisone with plans for outpatient rehabilitation.
Within 4 days of discharge, he was readmitted for wors-
ening lower extremity weakness, darkening urine, and
ongoing difficulties with managing secretions. He re-
ceived additional IVIG 500 mg/kg daily for 2 days
followed by initiation of rituximab 375 mg/m2 per week
for 4 weeks and cyclophosphamide 15 mg/kg on weeks 1
and 3 as induction therapy. An MRI of the thighs
confirmed ongoing muscle edema. His CK and anti-
HMGCR antibody levels began to stabilize, and then
improve as did his clinic symptoms. Figure 2 illustrates
his CK and anti-HMGCR antibody levels in relation to
his treatments. A repeat left thigh muscle biopsy showed
a myriad of necrotic fibers, accompanied by a large
number of regenerating fibers, all of which appeared to
Fig. 1 Neck CT Images. a Edema, stranding and exudates on initial presentation. b Worsening clinically after 4 days of antibiotic therapy. c Complete
resolution 2 weeks after immunosuppressive therapy
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be in the same stage of regeneration confirming prior
diagnosis of necrotizing myositis.
Subsequently, the patient was transferred to inpatient
rehabilitation where he had progressive improvement
in general fatigue, strength, and swallowing. He was
discharged home requiring minimal assistance and after
3 months resumed all his usual activities. He was sub-
sequently placed on methotrexate 15 mg weekly and a
prednisone was tapered over the next 4 months without
further complications.
Conclusion
Prior to this report, no severe head and neck involvement
has been described as the initial presentation of IMNM
that closely resembled severe infection. Otolaryngologists
may be consulted for head/neck involvement and severe
dysphagia and should be aware of HMGCR antibody
associated IMNM. Early recognition will allow for prompt
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